Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H21N5O2.ClH |
Molecular Weight | 351.831 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C
InChI
InChIKey=BRECEDGYMYXGNF-UHFFFAOYSA-N
InChI=1S/C16H21N5O2.ClH/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2;/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20);1H
Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other attributes related to emesis and prokinetics.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3397992 |
200.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Limican Approved UseAlizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. |
PubMed
Title | Date | PubMed |
---|---|---|
Hypertension and intravenous antidopaminergic drugs. | 1985 Apr 25 |
|
The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. | 1993 May-Jun |
|
Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. | 1994 Oct |
Patents
Sample Use Guides
The treatment duration should not exceed one week.
Oral administration: 100-200 mg per day in divided doses
Parenteral administration:
nausea and vomiting in pre-or post-operative, 50-200 mg, usually intramuscularly within 24 hours.
Nausea and vomiting during chemotherapy: 100 mg intravenously 20-30 minutes prior to chemotherapy treatment, followed by 50-100 mg intramuscularly 4-8 hours after the end of chemotherapy.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2901473
Alizapride inhibited binding of [3H]spiperone to rat striatal membrane preparations with the IC50 value of 66 nm.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1512
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
C200683
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
DTXSID20974759
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
100000088880
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
DBSALT000918
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
59338-87-3
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
6410734
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
41BT72BOQ7
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY | |||
|
SUB00345MIG
Created by
admin on Fri Dec 15 17:14:57 GMT 2023 , Edited by admin on Fri Dec 15 17:14:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD